Articles tagged with 'Research & Innovation' | Bayer

Newsroom Bayer (Research & Innovation)

2023
September
21,
2023
| 14:29 PM Europe/Amsterdam
Strategic expansion of Bayer’s portfolio in breast imaging / Companies to deliver innovative solutions on contrast-enhanced mammography (CEM) to imaging facilities / Collaboration to include education and hands-on training to support the safe and eff...
Read more
September
21,
2023
| 08:59 AM Europe/Amsterdam
Climate impacts estimated to have reduced farmer incomes by 15.7% on average over the past two years / Most pressing short-term challenges dominated by economic uncertainty and cost concerns / Yet 4 in 5 farmers have already taken or plan to take ste...
Read more
September
18,
2023
| 08:59 AM Europe/Amsterdam
Investigational VVD-130037 is highly specific, potent Kelch-like ECH Associated Protein 1 (KEAP1) activator developed for treatment of advanced solid tumors / Major milestone for Vividion’s chemoproteomics innovative technology platform / First-in-cl...
Read more
August
30,
2023
| 14:59 PM Europe/Amsterdam
Largest single investment in Crop Protection in Germany for 40 years / Focus on Environmental and Human Safety / State-of-the-art lab building and greenhouse / 5 floor main building; 28,000 m2 gross floor area / R&D facility offers space for 200 empl...
Read more
August
29,
2023
| 13:59 PM Europe/Amsterdam
New agreement will focus on CRISPR applications for Bayer’s Preceon™ Smart Corn System / Collaboration builds on successful initial gene-editing partnership between the two companies that resulted in 27 novel traits being transferred into Bayer’s tes...
Read more
August
28,
2023
| 07:59 AM Europe/Amsterdam
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year, exploratory clinical endpoints improved overall, with ...
Read more
August
24,
2023
| 10:29 AM Europe/Amsterdam
Three new investigator-sponsored collaborative studies are funded by Bayer and will evaluate the efficacy and safety of finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), in approximately 9,300 heart failure (HF) pati...
Read more
August
10,
2023
| 12:59 PM Europe/Amsterdam
Results from PULSAR demonstrate long term efficacy of aflibercept 8 mg with extended dosing intervals reaching up to 24 weeks and vision improvements comparable to Eylea™ (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients randomize...
Read more
August
03,
2023
| 13:58 PM Europe/Amsterdam
Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9.
Read more
August
03,
2023
| 13:29 PM Europe/Amsterdam
Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. / Agreement includes option for BlueRock to...
Read more
July
10,
2023
| 08:29 AM Europe/Amsterdam
Beijing, July 10, 2023 –Bayer and Peking University (PKU) will collaborate to foster the translation of basic pharmaceutical research into drug discovery and development, while accelerating scientific research on cutting-edge technologies across the ...
Read more
June
29,
2023
| 08:29 AM Europe/Amsterdam
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to EyleaTM (aflibercept 2 mg) at fixed 8-weekly dosing over two years / Patients assigned to a 16-week dosing regimen at baseline rec...
Read more
June
28,
2023
| 10:15 AM Europe/Amsterdam
R&D strategy poised to translate higher quality and productivity in Bayer’s innovation model into long-term growth in four key focus areas with high unmet patient needs / Shifting to breakthrough innovations based on new scientific approaches, platfo...
Read more
June
28,
2023
| 08:59 AM Europe/Amsterdam
Bayer’s projects in India, Bangladesh, Kenya, and Mexico/Honduras improve growers’ income and quality of life significantly, new analysis confirms / Majorities of around 70 to 90 percent of smallholder farmers surveyed report positive social benefits...
Read more
June
28,
2023
| 08:29 AM Europe/Amsterdam
Investigational Bemdaneprocel (BRT-DA01) was well tolerated with no major safety issues in all 12 patients through one year / Assessment of secondary endpoints demonstrates feasibility of transplantation and evidence of cell survival and engraftment ...
Read more
June
27,
2023
| 08:29 AM Europe/Amsterdam
Gadoquatrane is a highly stable contrast agent for magnetic resonance imaging (MRI) featuring high relaxivity with the potential for a substantially lower gadolinium (Gd) dose / QUANTI clinical development program includes two Phase III studies in ad...
Read more
June
22,
2023
| 08:29 AM Europe/Amsterdam
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) / CKD affects up to 40% of people with T1D / A quarte...
Read more
June
21,
2023
| 08:29 AM Europe/Amsterdam
Partnership will enhance clinical adoption of artificial intelligence (AI) in medical imaging  / AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity of radiology interventions...
Read more
June
15,
2023
| 08:59 AM Europe/Amsterdam
New post hoc analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will validate a model predicting the risk of chronic kidney disease (CKD) progression in adults at all stages of CKD / Update on FINEGUST study, descri...
Read more
June
05,
2023
| 08:30 AM Europe/Amsterdam
Clinically validated lipid nanoparticle (LNP) delivery technology will further strengthen Bayer’s gene therapy portfolio / High potency ionizable lipid technology and LNP carriers allow for efficient, targeted, and transient delivery of gene editing ...
Read more
June
01,
2023
| 08:29 AM Europe/Amsterdam
Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors / Assets are currently in pre-clinical development with potential to serve patients with high unmet need in underserved indications / Collabor...
Read more
May
25,
2023
| 13:59 PM Europe/Amsterdam
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 ...
Read more
May
17,
2023
| 13:59 PM Europe/Amsterdam
Chinese National Medical Products Administration granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase II...
Read more
May
16,
2023
| 13:11 PM Europe/Amsterdam
Funding advances BBI-355, a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor, through meaningful clinical data readouts in Phase 1/2 POTENTIATE clinical trial
Read more
May
16,
2023
| 08:29 AM Europe/Amsterdam
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in st...
Read more
May
11,
2023
| 07:29 AM Europe/Amsterdam
Four oral presentations and seven poster presentations will share insights into AskBio’s adeno-associated virus research, development and pre-clinical product progress / Breadth of research reinforces AskBio’s continued commitment to the development ...
Read more
May
10,
2023
| 09:59 AM Europe/Amsterdam
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macula...
Read more
May
09,
2023
| 08:59 AM Europe/Amsterdam
Poster presentation from the REALISE study, a real-world evidence analysis evaluating the status of treatment of vasomotor symptoms (VMS) and symptom burden in women taking adjuvant endocrine therapy (AET) after breast cancer, showing a need for new ...
Read more
May
04,
2023
| 22:15 PM Europe/Amsterdam
Global Bayer Co.Lab network of life science incubators established to accelerate innovation and foster collaborations within vibrant biotech ecosystems / U.S. flagship location opening in Cambridge, MA, encompasses state-of-the-art laboratories and c...
Read more
May
02,
2023
| 09:00 AM Europe/Amsterdam
Poster presentation on the EMPOWER study, a qualitative analysis from interviews with menopausal women, shows the importance of vasomotor symptoms (VMS), as well as potential treatment side effects on the women’s treatment decisions / Poster presenta...
Read more